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formation), TRACP (osteoclast number), and GAG release (cartilage
turnover). Overall cell viability was monitored using the dye Alamar Blue.
Passive release from metabolically inactive femur heads was measured
as background.
Results: Stimulation of the femur heads with RANKL, PTH, Il-1a and
OSM + TNF-a led to an increase in CTX-I release. Adding GM6001 to
OSM + TNF-a abrogated the release of CTX-I. Femur heads stimulated
with Il-1a, OSM + TNF-a and OSM + TNF-a + GM6001 induced an
increase in sGAG release. CTX-II release was increased by RANKL, PTH,
Il-1a, OSM + TNF-a and IGF-I. CTX-II release from the OSM + TNF-
a condition was abrogated when treated with GM6001. The osteoclast
marker TRACP increased when stimulated by RANKL, PTH, Il-1a, OSM +
TNF-a, OSM + TNF-a + GM6001. PIINP release was reduced when
stimulating with Il-1a, OSM + TNF-a, OSM + TNF-a + GM6001, whereas
PTH and IGF-I increased PIINP release.
Conclusions: We have established a whole tissue model for osteoarthri-
tis consisting of both cartilage and bone, and which is highly responsive
to both catabolic and anabolic stimulation. This is useful for testing
potential treatments for OA interfering with more than one aspect of
the pathological situation. Further it allows for investigating interactions
between cartilage and bone cell types.
Hopefully, future treatments for OA may be better identiﬁed after the
establishment of such a system for drug screening.
106 LOCALIZATION OF MMP- AND AGGRECANASE-GENERATED
NEO-EPITOPES IN OA ARTICULAR CARTILAGE
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M.A. Karsdal1, P. Qvist1. 1Nordic Bioscience A/S, Herlev, DENMARK,
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Purpose: MMP- and aggrecanase-mediated degradation of the cartilage
matrix, and aggrecan in particular, have been extensively studied in
cartilage explants as these two families of proteases are the most impor-
tant proteolytic enzymes involved in cartilage turnover. Catabolic stimu-
lated bovine explants cultures have been reported to release aggrecan-
fragments carrying aggrecanase-mediated neo-epitopes (e.g. the amino
acid sequence 374ARGSV. . . ) in the early phases, while the release
into the supernatant of fragments expressing the MMP-mediated neo-
epitopes (such as 342FFGVG. . . ) is delayed until the later stages. We
therefore wanted to investigate if this separation in time was reﬂected
in the differential localization of the aggrecan fragments in the cartilage
tissue. The overall aim of the study was to determine the localization of
aggrecan-related neo-epitopes in human sections of articular cartilage.
Methods: Human OA articular cartilage was obtained from knee replace-
ment surgery. Full depth biopsies were isolated from areas proximal
to lesions, followed by ﬁxing in paraformaldehyde, decalciﬁcation and
parafﬁn embedding. Sequential cartilage section were immunohistochem-
ically stained for presence of MMP and aggrecanase-mediated neo-
epitopes using monoclonal antibody AF28, BC-3 and 1H11 recognizing
the 342FFGVG. . . , the 374ARGSV. . . and the NITEGE373, respectively.
Results: IHC staining of the cartilage sections aggrecanase-mediated
aggrecan fragments in the proximity of the chondrocytes in the upper
zones. However, aggrecan fragments generated by aggrecanases – BC-3
and 1H11 – were found at the interface between the upper zone and the
superﬁcial layer. Since the superﬁcial layer is still present at this part
of the biopsies (low degree of erosion) it could depict the presence
of aggrecanases-mediated fragments at earlier stages of disease. In
contrast, MMP-mediated fragments were mainly observed in the upper-
mid zone where the superﬁcial layer was lost (high degree of erosion),
speciﬁcally in the surrounding of clusters.
Conclusions: Our immunehistochemistry results support earlier reports,
that the release of aggrecan fragments into the supernatant of the
catabolic stimulated explants cultures showed a bi-phasic pattern with
aggrecanase-mediated release at early time points and MMP-mediated
release of aggrecan fragments at the later stages. We speculate that
MMP and aggrecanases activity is related to disease states more than to
speciﬁc sites. Furthermore that MMP-mediated degradation is related to
areas with high cellular activity (e.g. clusters). The molecular mechanism
and sequence of events is still unclear, but current study gives some
direction to which path to follow.
107 WHOLE BLOOD LEAD (Pb) LEVELS AND PUTATIVE
OSTEOARTHRITIS BIOMARKERS IN AFRICAN AMERICAN
AND CAUCASIAN MEN: THE JOHNSTON COUNTY
OSTEOARTHRITIS PROJECT
J.M. Jordan1, F. Fang2, C. Brooks3, J.B. Renner1, T. Stabler4,
V.B. Kraus4. 1University of North Carolina School of Medicine, Chapel
Hill, NC, USA, 2StatWorks, Inc., RTP, NC, USA, 3Brevard College,
Brevard, NC, USA, 4Duke University Medical Center, Durham, NC, USA
Purpose: Lead (Pb) is a heavy metal that affects many aspects of
bone including osteoclasts, osteoblasts, and calcium and vitamin D
metabolism, and may have effects on cartilage as well. We have reported
associations between whole blood Pb levels and radiographic OA severity
in men and women, and with selected OA biomarkers in women. The
purpose of this analysis was to examine associations between putative
OA biomarkers and blood Pb levels in African American and white men.
Methods: A total of 333 men in the Johnston County OA Project Met-
als Exposure Sub-study (mean age 64.8 (10.7) years, 38.4% African
American) had available demographic and clinical data and whole blood,
serum, or urine samples for whole blood Pb and biomarkers assessments.
Whole blood Pb was measured by inductively coupled plasma mass
spectrometry at the Inorganic Toxicology laboratory, Division of Labora-
tory Sciences, National Center for Environmental Health, CDC, Atlanta,
Georgia. Urine C-telopeptide fragments of type II collagen (CTX-II), cross
linked N telopeptide of type I collagen (NTX-I), serum hyaluronic acid
(HA), cartilage oligometric matrix protein (COMP), and type II procollagen
(CPII) were measured by commercially available kits. Natural logarithm
(ln) transformation was used to produce distributions close to normality
for blood Pb and biomarkers. Spearman correlation coefﬁcients were
calculated between ln Pb and ln of each biomarker. Analysis of covariance
models were used to examine associations between blood Pb levels and
the 5 chosen biomarkers with ln transformed biomarkers as outcomes,
adjusting for age, race, and BMI. Effect modiﬁcation between ln Pb
and race were examined, with signiﬁcance deﬁned by p-values <0.1 for
interaction terms.
Results: Median Pb levels were 2.2 ug/dL (0.5−25.1) and were higher in
African American men than white men (p< 0.0001). In bivariate associa-
tions, ln Pb was correlated with ln CTX-II (r = 0.12, p = 0.035) and ln COMP
(r = 0.20, p< 0.0002), but not with ln NTX-I, ln HA, or ln CPII (r = 0.02,
0.0008, and 0.13, respectively, p> 0.13). In adjusted models, ln Pb was
associated with mean ln CTX-II (p = 0.024) and COMP (p=0.0001). There
were no notable race and ln Pb interactions.
Conclusions: Mean blood Pb levels were associated with urine CTX-II
and serum COMP, but not serum HA or CPII in both African American
and white men. These data suggest that Pb may have an effect on type II
collagen and non-collagenous matrix proteins. Potential effects of Pb in
the pathogenesis of OA, then, are likely to be related to alterations in
these factors, but less likely to effects on synovial inﬂammation.
108 AUROTHIOMALATE INHIBITS COX-2 EXPRESSION AND
PGE2 PRODUCTION IN CHONDROCYTES BY INCREASING
MKP-1 EXPRESSION AND DECREASING p38 AND JNK
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Purpose: Disease-modifying anti-rheumatic drugs (DMARDs) suppress
inﬂammation, and retard cartilage degradation and bone erosion in arthri-
tis. The molecular mechanisms of action of many traditional DMARDs are
not known in detail. Inducible prostaglandin synthase (cyclooxygenase-2,
COX-2) is highly expressed in OA and RA cartilage and it produces
high amounts of proinﬂammatory prostanoids in the joint. The signaling
mechanisms involved in the up-regulation of COX-2 in chondrocytes are
not known in detail. In the present study we investigated the effects
of DMARDs on mitogen-activated protein kinase (MAPK) pathways and
MAP kinase phosphatase-1 (MKP-1) in immortalized H4 chondrocytes*.
Methods: PGE2 production was measured by RIA, protein expression
was measured by Western blot and mRNA expression was measured by
quantitative PCR.
Results:We investigated the effects of traditional DMARDs on MKP-1 ex-
pression in chondrocytes. Unlike the other tested compounds (cyclosporin
A, hydroxychloroquine, leﬂunomide, its active metabolite A771726,
methotrexate and sulfasalazine), aurothiomalate was found to enhance
MKP-1 expression. Aurothiomalate inhibited Il-1b-induced COX-2 expres-
sion and prostaglandin E2 (PGE2) production by destabilizing COX-2
mRNA as did p38 MAPK inhibitor SB203580. Interestingly, aurothiomalate
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inhibited the phosphorylation of p38 and JNK kinases along with its
enhancing effect on MKP-1 expression; and when MKP-1 was down-
regulated by siRNA, aurothiomalate’s ability to inhibit p38 and JNK
phosphorylation, and COX-2 expression reduced signiﬁcantly.
Conclusions: The results provide a novel mechanism for the anti-
inﬂammatory action of aurothiomalate through increased MKP-1 expres-
sion and reduced p38 and JNK MAP-kinase activation, and COX-2
expression. The results propose MKP-1 as a promising novel target for
the development of disease modifying drugs for RA and OA.
*Murine H4 chondrocyte cell line was kindly provided by Peter van der
Kraan, Laboratory of Experimental Rheumatology, University Medical
Center Nijmegen, Netherlands.
109 IDENTIFICATION OF AGGRECANASES-MEDIATED
AGGRECAN FRAGMENT CIRCULATING IN HUMAN PLASMA
FROM PATIENTS SUFFERING FROM RHEUMATOID
ARTHRITIS (RA)
J-C. Rousseau1, C. Bertholon1, I. Byrjalsen2, P. Miossec3, P. Delmas1,
P. Qvist2. 1INSERM 831, Lyon, FRANCE, 2Nordic Bioscience, Herlev,
DENMARK, 3Department of Immunology and Rheumatology, E. Herriot
Hospital, Lyon, FRANCE
Purpose: Aggrecan, the main proteoglycan of articular cartilage, is
composed of a core protein containing 3 globular domains G1, G2 and
G3. The interglobular domain between G1 and G2 is the primary site for
enzyme attacks of the molecule, matrix metalloproteinases (MMPs) and
aggrecanases, generating fragments with speciﬁc N-terminal ends. The
aim of this study was to identify aggrecan fragments circulating in hu-
man serum/plasma with speciﬁc antibodies corresponding to neoepitope
generated by aggrecanases.
Methods: Pools of serum from controls (n = 22; mean age: 62 yrs ±2.7)
and patients suffering from osteoarthritis (n = 19; mean age: 64±4) and
plasma from patients suffering from RA (n= 20; 10 men and 10 women,
mean age: 61.7 yrs ±3.9, DAS> 4.8) were investigated with afﬁnity
puriﬁcation and Western blots using two monoclonal antibodies. First,
monoclonal antibody BC-3 recognizing a neoepitope generated by aggre-
canases in position 374-ARGSV. Secondly, a monoclonal antibody F-78
was used recognizing a repetitive epitope exposed at least twice on G1
and G2 domains.
Results: In Western blot, BC-3 recognized a band migrating at 45 kDa in
RA patients only. The strong reactivity was abolished by pre-incubation
with the peptide corresponding to BC-3 epitope. To further investigate the
distribution of ARGSV-carrying neoepitopes in RA plasma, we subjected
the plasma to afﬁnity puriﬁcation using either BC-3 or F-78. Again, the
major reactivity was conﬁned to a 45 kDa band using either BC-3 or F-78
as detecting antibody in western blots of the eluted material.
Conclusions: We have identiﬁed an aggrecan fragment of MW 45 kDa
generated by aggrecanase cleavage with a N-terminal neoepitope 374-
ARGSV and containing G2 domain suggesting that this fragment is a
good candidate marker for a sandwich assay using monoclonal antibodies
BC-3 and F-78. Apparently, this fragment of aggrecan is primarily found
in circulation of RA patients and additional investigations are underway
to determine the molecular nature of this fragment.
110 NEW BIOCHEMICAL MARKERS OF COLLAGEN TYPE II
DEGRADATION
I. Byrjalsen1, J. Wang2, P. Qvist1, P.G. Mitchell3, K.L. Dufﬁn3,
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Purpose: One hallmark of the progression of osteoarthritis and rheuma-
toid arthritis is the gradual destruction of articular cartilage in affected
joints, in part mediated the matrix metalloproteases (MMPs) and aggre-
canases. Collagen type II is found almost exclusively in cartilage tissue
where it constitutes over 60% of the dry weight. Degradation of collagen
type II is for the major part mediated by MMPs. Because of the abundance
of collagen type II in cartilage and its tissue speciﬁcity, MMP generated
fragments of type II collagen (neo-epitopes) are highly interesting as
cartilage degradation markers. The aim of this study was to develop
new biochemical enzyme immuno assays (EIA) of MMP cleaved collagen
type II fragments to be used as markers of cartilage degradation.
Methods: Two neoepitopic sites representing ubiquitous MMP-generated
fragments of collagen type II identiﬁed from cleavage of collagen type II
were selected. The two neoepitopes corresponded to cleavage between
amino acids 845–846 (neoepitope I) and 872–873 (neoepitope II).
Peptides reﬂecting the neoepitopic sites (846LTGPAG and RDGAAG872)
were synthesized and used for immunization of balb/C mice and rabbits.
Competitive EIA assays were established using biotinylated synthetic
peptide as coater and the immune sera as primary antibody. The assays
were used to proﬁle the proteolytic events in the well characterized ex vivo
articular cartilage explant model. The cartilage explants included catabol-
ically stimulated TNFa (tumor necrosis factor alpha) and oncostatin M
cultures, non-stimulated cultures, and metabolically inactive cultures.
Results: In catabolically stimulated bovine cartilage explant cultures a
low concentration of neoepitope I of below 50ng/ml was found in samples
collected day 3, 6, and day 11. However after prolonged catabolic stim-
ulation of 22 days a more than 20-fold dramatic increase was observed
reaching a level higher than 1000 ng/ml. In comparison the control culture
of non-stimulated explant culture media had the same low level below
50ng/ml on day 3, 6, and 11, and reached only 100 ng/ml at day 22.
The metabolically inactive culture remained below 50ng/ml during the
complete culture period. A similar pattern of a dramatic increase in the
22-day catabolically stimulated culture was observed in human articular
cartilage explant cultures. The pattern of other marker of neopitope II
mirrored that of neoepitope I.
Conclusions: Two new immunoassays of neoepitope markers of collagen
type II degradation were established. Measurement of these neoepitopes
in both the bovine and human ex vivo articular cartilage explant model
demonstrated that the two markers reﬂect late cartilage degradation.
Further studies are needed to investigate whether these fragments are
of clinical relevance.
111 CHANGES IN SERUM CARTILAGE OLIGOMERIC MATRIX
PROTEIN CONCENTRATION AFTER 12 WEEKS IMPACT OR
NON-IMPACT EXERCISES
O. Celik1, Y. Salci1, F. Korkusuz1, A. Kalaci2. 1Middle East Technical
University, Ankara, TURKEY, 2Mustafa Kemal University, Hatay,
TURKEY
Purpose: The objective of the present study was to investigate the
changes of serum level of cartilage oligomeric matrix protein (COMP)
during a 30-min exercise after 12-weeks of regular impact or non-impact
exercise.
Methods: Blood samples were drawn from 33 healthy sedanter males
immediately before and after and 0.5 h after a 30-min walking exercise
on a motor-driven treadmill at 5 km/h speed. Serum COMP concentra-
tions were determined using a commercial enzyme-linked immunosorbent
assay (AnaMar Medical, Go¨teborg, Sweden). After ﬁrst measurements
participants were randomly and equally assigned to impact group (run-
ning, n = 11) non-impact group (swimming, n = 11), and control conditions
(n = 11). All exercise groups participated in sessions of 40 minutes per
day, 3 days per week for 12 weeks. Each session started with a 5min.
of warm-up, continuing with main set for 30min. at their individual target
heart rate zone which was determined according to the ACSMs’ guide-
lines (60−70% of heart rate reserve) and lasted with a 5min. cool down
period. The target heart rate reserve (HRR) was determined by Karvo-
nen formula (Bompa, 1994). Participants in running and cycling groups
partake sessions in the human performance laboratory one by one, three
times a week throughout their weekly Schedule (throughout Mondays,
Wednesdays and Fridays) which was determined by the instructor while
swimming group perform exercise sessions in indoor swimming pool. The
heart rate of the subjects was monitored with Heart rate monitors (Polar
Vantage NV Heart Rate Monitor) during exercise sessions. Throughout
the 12-week period, the control group was told not to participate in any
organized or structured exercise and continue their daily life activities.
At the end of the 12-weeks intervention period, post tests were applied
with the same procedure of pre-tests. The experimental protocol was
approved by local ethics committee. All subjects signed a consent form
after being fully informed of the study’s methods, possible side effects and
the purpose. Serum COMP concentrations within the groups of running,
swimming and control were compared using separate repeated measures
of analysis of variance (repeated-ANOVA). Main effect was compared
for multiple comparisons by Bonferroni conﬁdence interval adjustment.
Statistical computation was performed using the SPSS. The level of
statistical signiﬁcance was accepted as p< 0.05.
Results: In the pre-tests measurements, signiﬁcant change between the
serum COMP concentrations were found only at P< 0.1 level. Immediately
after the walking exercise, serum COMP concentrations were increased
signiﬁcantly in running (P=0.084) and control groups (P=0.064). In the
